Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H2NVAC in HER2-Expressing DCIS
NCT04144023Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Jun 2019
- Primary completion
- Dec 2027
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of multi-epitope HER2 peptide vaccine H2NVAC in ductal carcinoma in situ (DCIS), sponsored by Mayo Clinic. Primary endpoints: Adverse events at 2 years and Dose limiting toxicities at 2 years. Started Jun 2019; status: recruiting.
02
Drugs
multi-epitope HER2 peptide vaccine H2NVAC
03
Conditions
ductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NCT04144023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04144023.